Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Letermovir Versus Valganciclovir for 90 Days in CMV Seropositive Kidney Transplant Recipients: Results of a Single-center Experience.

NCT07571135 is registered in ClinicalTrials.gov with Elisabeth Kincaide as lead sponsor.

NCT NCT07571135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07571135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Letermovir Versus Valganciclovir for 90 Days in CMV Seropositive Kidney Transplant Recipients: Results of a Single-center Experience.
Lead sponsor
Elisabeth Kincaide
Phase
Phase 4
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
November 30, 2028
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cmv, cmv disease, cmv infection, cmv viremia